Hepatitis C virus: the burden of the disease

Area of Science:

• Hepatology
• Virology
• Public Health

Background:

• Chronic hepatitis C virus (HCV) infection affects 3% of the global population, contributing significantly to cirrhosis, end-stage liver disease, and hepatocellular carcinoma.
• The healthcare burden of HCV is projected to rise substantially over the next 15 years without a coordinated national strategy.
• HCV's epidemic peak occurred in the 1980s, highlighting the long-term impact of this viral infection.

Purpose of the Study:

• To summarize the current landscape of chronic hepatitis C infection.
• To discuss diagnostic approaches and the evolving role of fibrosis assessment.
• To emphasize the need for strategic interventions to manage the growing public health challenge.

Main Methods:

• Review of current diagnostic tools for hepatitis C virus (HCV) infection, including third-generation enzyme immunoassays and molecular assays.
• Evaluation of non-invasive markers and composite scores for liver fibrosis assessment.
• Analysis of the clinical recommendations for liver biopsy in managing chronic HCV.

Main Results:

• Hepatitis C infection is readily diagnosable using established serological and molecular methods.
• Non-invasive fibrosis assessment tools show promise in potentially replacing liver biopsy in certain clinical scenarios.
• Liver biopsy remains indicated for patients with chronically elevated transaminases and those requiring antiviral therapy.

Conclusions:

• Effective diagnosis of chronic hepatitis C is achievable with current technologies.
• Non-invasive methods for assessing liver fibrosis are emerging as valuable alternatives to liver biopsy.
• Proactive national strategies are essential to manage the escalating public health impact of hepatitis C.